Monte Rosa Therapeutics (GLUE) Projected to Post Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.24) per share and revenue of $13.57 million for the quarter.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.60. The firm had revenue of $14.00 million during the quarter, compared to the consensus estimate of $43.73 million. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Stock Down 6.5 %

Shares of GLUE stock traded down $0.30 during trading on Tuesday, hitting $4.33. The company had a trading volume of 111,637 shares, compared to its average volume of 1,048,902. Monte Rosa Therapeutics has a 52 week low of $3.21 and a 52 week high of $12.40. The stock has a market capitalization of $266.34 million, a price-to-earnings ratio of -2.37 and a beta of 1.52. The stock's 50-day moving average is $5.17 and its two-hundred day moving average is $6.57.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $17.00 target price (up previously from $15.00) on shares of Monte Rosa Therapeutics in a report on Thursday, March 20th. Wells Fargo & Company dropped their price objective on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating on the stock in a report on Friday, March 21st. Finally, Lifesci Capital started coverage on Monte Rosa Therapeutics in a report on Wednesday, March 12th. They set an "outperform" rating and a $19.00 price target for the company.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, Director Chandra P. Leo purchased 10,000 shares of the business's stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average price of $5.84 per share, for a total transaction of $58,400.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $58,400. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.50% of the company's stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.